STORY SUMMARY
Boyd Huppert, widely recognized by viewers of the “Land of 10,000 Stories,” has shared a personal battle with multiple myeloma. In a heartfelt interview with colleague Rena Sargen Poulos, Boyd revealed a recent setback following his bone marrow transplant 2.5 years ago, but also expressed hope in a groundbreaking new therapy. The FDA recently approved CAR T-cell treatment, which leverages the patient’s own T-cells to fight the cancer. Boyd is the first patient to be enrolled for this treatment as second-line therapy. While not a cure, it brings new hope for him and other cancer patients. Boyd remains optimistic and resilient, continuing to inspire his family and viewers as he embarks on this new phase of treatment.
VIDEO
FULL STORY
Boyd Hooper, widely recognized for his compelling narratives in the “Land of 10,000 Stories,” is currently navigating an arduous journey of his own against multiple myeloma. During a discussion with colleague Rena Sargen Poulos, Hooper revealed a recent downturn in his health, stemming from the resurfacing of his cancer post a bone marrow transplant two and a half years ago. Although the prognosis wasn’t what Hooper hoped for, he holds onto a renewed sense of optimism thanks to a newly approved, innovative treatment that may benefit other patients as well.
Hooper’s doctors have embarked on a novel approach involving CAR T cell therapy, a groundbreaking treatment that reprograms the patient’s own T cells to target the cancer. This therapy, freshly endorsed by the FDA for multiple myeloma, had not been available at the time of Hooper’s diagnosis. Clear indications of hope emerged as Dr. Amy Marino discussed how this therapy utilizes the body’s immune system, transforming T cells into a living drug that continually engages with and dismantles the cancer cells. Although not a cure, the treatment signifies a pivotal moment of extended hope in Hooper’s battle.
While CAR T cell therapy positions Boyd Hooper for potentially more years to come, he reflects on the extra time granted by his previous bone marrow transplant with deep gratitude. Over the past two years, Hooper continued to immerse himself in work, travel with his wife Sherry, and welcome his granddaughter, Tess, into the world. As he now prepares for this next crucial phase of treatment, the broader medical community watches with keen interest. The advancements in oncology and the swift pace of medical innovations suggest a promising future, possibly edging closer to a cure for conditions like multiple myeloma in Hooper’s lifetime.
